

1. Macintyre W. Case of mollities and fragilitas ossium, accompanied with urine strongly charged with animal matter. *Med Chir Trans* 1859;33:211–232.
2. Bence J. On a new substance occurring in the urine of a patient with mollities and fragilitas ossium. *Phil Trans R Soc Lond* 1848;55:673.
3. Kahler O. Zur Symptomatologie des multiplen Myeloma: beobachtung von Albumosurie. *Prog Med Wochenschr* 1889;14:33.
4. Arinkin M. Die intravitale Untersuchungs-Methodik des Knochenmarks. *Folia Haematol (Lepiz)* 1929;38:233.
5. Tiselius A. Electrophoresis of serum globulin. II. Electrophoretic analysis of normal and immune sera. *Biochem J* 1937;31:1464–1477.
6. Chauthan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF- $\kappa$ B. *Blood* 1996;87:1104–1112.
7. Chauhan D, Anderson KC. *Cytokines and Signal Transduction in Multiple Myeloma* (4th ed.). Cambridge, UK: Cambridge University Press; 2001.
8. Holland JR, Hosley H, Scharlau C, et al. A controlled trial of urethane treatment in multiple myeloma. *Blood* 1966;27:328–342.
9. Bergsagel D. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). *Cancer Chemother Rep* 1962;21:87–99.
10. Salmon SE, Shaddock RK, Schilling A. Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma. *Cancer Chemother Rep* 1967;51:179–187.
11. Alexanian R, Bonnet J, Gehan E, et al. Combination chemotherapy for multiple myeloma. *Cancer* 1972;30:382–389.
12. McElwain T, Powles R. High-dose intravenous melphalan for plasma-cell leukemia and myeloma. *Lancet* 1983;1:822–824.
13. Cohen HJ, Crawford J, Rao MK, et al. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. *Am J Med* 1998;104:439–444.
14. Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. *Mayo Clin Proc* 2007;82:1468–1473.
15. Landgren O, Graubard BI, Katzmann JA, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey. *Leukemia* 2014;28:1537–1542.
16. Riedel DA, Pottern LM. The epidemiology of multiple myeloma. *Hematol Oncol Clin North Am* 1992;6:225–247.
17. Ichimaru M, Ishimaru T, Mikami M, et al. Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950–76: relationship to radiation dose absorbed by marrow. *J Natl Cancer Inst* 1982;69:323–328.
18. Bergsagel DE, Wong O, Bergsagel PL, et al. Benzene and multiple myeloma: appraisal of the scientific evidence. *Blood* 1999;94:1174–1182.
19. Lundberg I, Milatou-Smith R. Mortality and cancer incidence among Swedish paint industry workers with long-term exposure to organic solvents. *Scandinavian J Work Environ Health* 1998;24:270–275.
20. Salmon SE, Kyle RA. Silicone gels, induction of plasma cell tumors, and genetic susceptibility in mice: a call for epidemiologic investigation of women with silicone breast implants. *J Natl Cancer Inst* 1994;86:1040–1041.
21. Doody MM, Linet MS, Glass AG, et al. Risks of non-Hodgkin's lymphoma, multiple myeloma, and leukemia associated with common medications. *Epidemiology* 1996;7:131–139.
22. Linet MS, Harlow SD, McLaughlin JK. A case-control study of multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug use. *Cancer Res* 1987;47:2978–2981.
23. Brown LM, Linet MS, Greenberg RS, et al. Multiple myeloma and family history of cancer among blacks and whites in the U.S. *Cancer* 1999;85:2385–2390.
24. Grosbois B, Jegou P, Attal M, et al. Familial multiple myeloma: report of fifteen families. *Br J Haematol* 1999;105:768–770.
25. Weinhold N, Johnson DC, Chubb D, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. *Nat Genet* 2013;45:522–525.
26. Weinhold N, Johnson DC, Rawstron AC, et al. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. *Blood* 2014;123:2513–2517.
27. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. *N Engl J Med* 2002;346:564–569.
28. Avet-Loiseau H, Facon T, Daviet A, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. *Cancer Res* 1999;59:4546–4550.
29. Seligmann M, Sassy C, Chevalier A. A human IgG myeloma protein with anti-2 macroglobulin antibody activity. *J Immunol* 1973;110:85–90.
30. Malik AA, Canti AK, Potti A, et al. Role of *Helicobacter pylori* infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. *Am J Gastroenterol* 2002;97:1371–1374.
31. Rajkumar SV, Kyle RA, Plevak MF, et al. *Helicobacter pylori* infection and monoclonal gammopathy of undetermined significance. *Br J Haematol* 2002;119:706–708.
32. Konrad RJ, Kricka LJ, Goodman DB, et al. Brief report: myeloma-associated paraprotein directed against the HIV-1 p24 antigen in an HIV-1-seropositive patient. *N Engl J Med* 1993;328:1817–1819.
33. Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. *Blood* 2009;113:5412–5417.
34. Brown LM, Gridley G, Check D, et al. Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. *Blood* 2008;111:3388–3394.
35. Rettig MB, Ma HJ, Vescio RA, et al. Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients [see comments]. *Science* 1997;276:1851–1854.
36. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castlemann's disease [see comments]. *Blood* 1995;86:1276–1280.
37. Said W, Chien K, Takeuchi S, et al. Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. *Blood* 1996;87:4937–4943.
38. Schalling M, Ekman M, Kaaya EE, et al. A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma. *Nat Med* 1995;1:707–708.
39. Cull GM, Carter GI, Timms JM, et al. Low incidence of human herpesvirus 8 in stem cell collections from myeloma patients. *Bone Marrow Transplant* 1999;23:759–761.
40. Tarte K, Chang Y, Klein B. Kaposi's sarcoma-associated herpesvirus and multiple myeloma: lack of criteria for causality. *Blood* 1999;93:3159–3163.
41. Yi Q, Ekman M, Anton D, et al. Blood dendritic cells from myeloma patients are not infected with Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8). *Blood* 1998;92:402–404.
42. Tarte K, Olsen SJ, Yang Lu Z, et al. Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirus. *Blood* 1998;91:1852–1857.
43. Brander C, Raje N, O'Connor PG, et al. Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. *Blood* 2002;100:698–700.
44. Sahota SS, Davis Z, Hamblin T, et al. Discordant somatic mutation of immunoglobulin variable region genes and bcl-6 genes in chronic lymphocytic leukemia. *Blood* 1999;94:662a.
45. Davies FE, Dring AM, Li C, et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. *Blood* 2003;102:4504–4511.
46. Avet-Loiseau H, Li JY, Morineau N, et al. Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome. *Blood* 1999;94:2583–2589.
47. Weiss BM, Abadie J, Verma P, et al. A monoclonal gammopathy precedes multiple myeloma in most patients. *Blood* 2009;113:5418–5422.
48. Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. *Blood* 2002;100:1417–1424.
49. Kaufmann H, Ackermann J, Baldia C, et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. *Leukemia* 2004;18:1879–1882.
50. Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. *J Clin Oncol* 2013;31:4325–4332.
51. Potter M. Experimental plasmacytomagenesis in mice. *Hematol Oncol Clin North Am* 1997;11:323–347.
52. Radl J. Multiple myeloma and related disorders. Lessons from an animal model. *Pathol Biol (Paris)* 1999;47:109–114.
53. Sawyer J, Waldron J, Jagannath S, et al. Cytogenetics findings in 200 patients with multiple myeloma. *Cancer Genet Cytogenet* 1995;82:41–49.
54. Sawyer JR, Lukacs JL, Thomas EL, et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. *Br J Haematol* 2001;112:167–174.
55. Perez-Simon JA, Garcia-Sanz R, Tabernero MD, et al. Prognostic value of numerical chromosome aberrations in multiple myeloma: a FISH analysis of 15 different chromosomes. *Blood* 1998;91:3366–3371.
56. Rasillo A, Tabernero MD, Sanchez ML, et al. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia. *Cancer* 2003;97:601–609.
57. Chng WJ, Van Wier SA, Ahmann GJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. *Blood* 2005;106:2156–2161.
58. Hallek M, Bergsagel LP, Anderson KD. Multiple myeloma: increasing evidence for a multistep transformation process. *Blood* 1998;91:3–21.
59. Dewald GW, Kyle RA, Hicks GA, et al. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. *Blood* 1985;66:380–390.

60. Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. *Blood* 1995;86:3915–3921.
61. Hayman SR, Bailey RJ, Jalal SM, et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. *Blood* 2001;98:2266–2268.
62. Chesi M, Bergsagel PL, Brents LA, et al. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines [see comments]. *Blood* 1996;88:674–681.
63. Hart KC, Robertson SC, Kanemitsu MY, et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. *Oncogene* 2000;19:3309–3320.
64. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. *Nat Genet* 1997;16:260–264.
65. Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. *Blood* 2001;97:729–736.
66. Plowright EE, Li Z, Bergsagel PL, et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. *Blood* 2000;95:992–998.
67. Chesi M, Bergsagel PL, Shonukan OO, et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. *Blood* 1998;91:4457–4463.
68. Iida S, Rao PH, Butler M, et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. *Nat Genet* 1997;17:226–230.
69. Mahmoud MS, Huang N, Nobuyoshi M, et al. Altered expression of Pax-5 gene in human myeloma cells. *Blood* 1996;87:4311–4315.
70. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. *Proc Natl Acad Sci U S A* 2000;97:228–235.
71. Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. *Blood* 2001;98:3082–3086.
72. Selvanayagam P, Blick M, Narni F, et al. Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma. *Blood* 1988;71:30–35.
73. Greil R, Fasching B, Loidl P, et al. Expression of the C-Myc proto-oncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis. *Blood* 1991;78:180–191.
74. Tricot C, Sawyer J, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletion of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. *Blood* 1995;86:4250–4256.
75. Dao DD, Sawyer JR, Epstein J, et al. Deletion of the retinoblastoma gene on multiple myeloma. *Leukemia* 1994;8:1280–1284.
76. Shaughnessy J, Barlogie B. Chromosome 13 deletion in myeloma. *Curr Top Microbiol Immunol* 1999;246:199–203.
77. Urashima M, Ogata A, Chauhan D, et al. Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein. *Blood* 1996;88:2219–2227.
78. Ng MH, Chung YF, Lo KW, et al. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. *Blood* 1997;89:2500–2506.
79. Urashima M, Teoh G, Ogata A, et al. Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia. *Clin Cancer Res* 1997;3:2173–2179.
80. Kawano MM, Mahmoud MS, Ishikawa H. Cyclin D1 and p16(INK4A) are preferentially expressed in immature and mature myeloma cells, respectively. *Br J Haematol* 1997;99:131–138.
81. Neri A, Baldini L, Trecca D, et al. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. *Blood* 1993;81:128–135.
82. Portier M, Moles JP, Mazars GR, et al. p53 and RAS gene mutations in multiple myeloma. *Oncogene* 1992;7:2539–2543.
83. Teoh G, Urashima M, Ogata A, et al. MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. *Blood* 1997;90:1982–1992.
84. Pettersson M, Jernberg-Wiklund H, Larsson LG, et al. Expression of the Bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. *Blood* 1992;79:495–502.
85. Puthier D, Pellat-Deceunynck C, Barille S, et al. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. *Leukemia* 1999;13:289–294.
86. Gazitt Y, Fey V, Thomas C, et al. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells. *Int J Oncol* 1998;13:397–405.
87. Iyer R, Ding L, Batchu RB, et al. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma. *Leuk Res* 2003;27:73–78.
88. Sangfelt O, Osterborg A, Grandt D, et al. Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. *Int J Cancer* 1995;63:190–192.
89. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. *Immunity* 1999;10:105–115.
90. Hideshima T, Mitsiades C, Ikeda H, et al. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. *Blood* 2010;115:3772–3775.
91. Shamma MA, Shmookler Reis RJ, Akiyama M, et al. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. *Mol Cancer Ther* 2003;2:825–833.
92. Bergsagel DE, Kuehl M, Zhan F, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. *Blood* 2005;106:296–303.
93. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. *Blood* 2007;109:2276–2284.
94. Decaux O, Lode L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergrupe Francophone du Myelome. *J Clin Oncol* 2008;26:4798–4805.
95. Broyl A, Hose D, Lokhorst H, et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. *Blood* 2010;116:2543–2553.
96. Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. *J Clin Oncol* 2009;27:4585–4590.
97. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. *Cell* 2011;146:904–917.
98. Kaiser MF, Johnson DC, Wu P, et al. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. *Blood* 2013;122:219–226.
99. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. *Proc Natl Acad Sci U S A* 2008;105:12885–12890.
100. Gutierrez NC, Sarasquete ME, Misiewicz-Krzeminska I, et al. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. *Leukemia* 2010;24:629–637.
101. Pichiorri F, Suh SS, Rocci A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. *Cancer Cell* 2008;18:367–381.
102. Leone E, Morelli E, Di Martino MT, et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. *Clin Cancer Res* 2013;19:2096–2106.
103. Amodio N, Bellizzi D, Leotta M, et al. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. *Cell Cycle* 2013;12:3650–3662.
104. Di Martino MT, Leone E, Amodio N, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. *Clin Cancer Res* 2012;18:6260–6270.
105. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. *Nature* 2011;471:467–472.
106. Magrangeas F, Avet-Loiseau H, Gouraud W, et al. Minor clone provides a reservoir for relapse in multiple myeloma. *Leukemia* 2013;27:473–481.
107. Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. *Nat Commun* 2014;5:2997.
108. Dhodapkar MV, Kelly T, Theus A, et al. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma [published erratum appears in *Br J Haematol* 1998 May;101(2):398]. *Br J Haematol* 1997;99:368–371.
109. Yang Y, Yaccoby S, Liu W, et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. *Blood* 2002;100:610–617.
110. Chauhan D, Uchiyama H, Urashima M, et al. Regulation of interleukin-6 in multiple myeloma and bone marrow stromal cells. *Stem Cells* 1995;15:35–39.
111. Hideshima T, Chauhan D, Schlossman R, et al. The role of Tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. *Oncogene* 2001;20:4519–4527.
112. Dankar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. *Blood* 2000;95:2630–2636.
113. Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. *Mol Cancer Ther* 2002;1:539–544.
114. Tai YT, Podar K, Catley L, et al. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3-kinase/AKT signaling. *Cancer Res* 2003;63:5850–5858.
115. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. *Cancer Cell* 2007;12:131–144.
116. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. *Cancer Cell* 2007;12:115–130.

117. Demchenko YN, Glebov OK, Zingone A, et al. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. *Blood* 2010;115:3541–3552.
118. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. *Br J Haematol* 1994;87:503–508.
119. Rajkumar SV, Fonseca R, Witzig TE, et al. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. *Leukemia* 1999;13:469–472.
120. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. *Clin Cancer Res* 2002;8:2210–2216.
121. Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. *Semin Oncol* 2001;28:565–569.
122. Kumar S, Fonseca R, Dispenzieri A, et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy. *Br J Haematol* 2002;119:665–671.
123. Bellamy WT, Richter L, Frutiger Y, et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. *Cancer Res* 1999;59:728–733.
124. Seidel C, Borset M, Turesson I, et al. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. *Blood* 1998;91:806–812.
125. Chauhan D, Singh AV, Brahmandam M, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. *Cancer Cell* 2009;16:309–323.
126. Urashima M, Ogata A, Chauhan D, et al. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. *Blood* 1996;87:1928–1938.
127. Brenne AT, Baade Ro T, Waage A, et al. Interleukin-21 is a growth and survival factor for human myeloma cells. *Blood* 2002;99:3756–3762.
128. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. *Oncogene* 2002;21:5673–5683.
129. Qiang YW, Kopantzev E, Rudikoff S. Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. *Blood* 2002;99:4138–4146.
130. Akiyama M, Hideshima T, Hayashi T, et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. *Cancer Res* 2002;62:3876–3882.
131. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. *Blood* 2001;98:428–435.
132. Podar K, Tai YT, Lin BK, et al. Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. *J Biol Chem* 2002;277:7875–7881.
133. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. *Leukemia* 2001;15:1950–1961.
134. Lin B, Podar K, Gupta D, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. *Cancer Res* 2002;62:5019–5026.
135. Prabhala RH, Pelluru D, Fulcinotti M, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. *Blood* 2010;115:5385–5392.
136. Gieseler F, Nussler V. Cellular resistance mechanisms with impact on the therapy of multiple myeloma. *Leukemia* 1998;12:1009–1012.
137. Raaijmakers HG, Izquierdo MA, Likhorskiy HM, et al. Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. *Blood* 1998;91:1029–1036.
138. Pilarski LM, Jensen GS. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. *Hematol Oncol Clin North Am* 1992;6:297–322.
139. Jensen GS, Mant MJ, Belch AJ, et al. Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B cells. *Blood* 1991;78:711–719.
140. Hata H, Xiao HQ, Petrucci MT, et al. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature myeloma cells. *Blood* 1993;81:3357–3364.
141. Kawano MM, Huang N, Harada H, et al. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. *Blood* 1993;82:564–570.
142. Epstein J, Barlogie B, Katzmann J, et al. Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement. *Blood* 1988;71:861–865.
143. Kawano MM, Mahmoud MS, Huang N, et al. High proportions of VLA-5-immature myeloma cells correlated well with poor response to treatment in multiple myeloma. *Br J Haematol* 1995;91:860–864.
144. Robillard N, Jego C, Pellat-Deceunynck C, et al. CD28, a marker associated with tumoral expansion in multiple myeloma. *Clin Cancer Res* 1998;4:1521–1526.
145. Treon SP, Shima Y, Preffer FI, et al. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. *Semin Oncol* 1999;26:97–106.
146. Thomas X, Xiao HQ, Chang R, et al. Circulating B lymphocytes in multiple myeloma patients contain an autocrine IL-6 driven pre-myeloma cell population. *Curr Top Microbiol Immunol* 1992;182:201–207.
147. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. *Blood* 2004;103:2332–2336.
148. Pilarski LM, Andrews EJ, Mant MJ, et al. Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function. *J Clin Immunol* 1986;6:491–501.
149. Munshi NC. Immunoregulatory mechanisms in multiple myeloma. *Hematol Oncol Clin North Am* 1997;11:51–69.
150. Ludwig H, Fritz E. [Lymphocyte subpopulations in multiple myeloma. Shift in the helper/suppressor cell relation]. *Acta Medica Austriaca* 1982;9:215–220.
151. Mellstedt H, Holm G, Pettersson D, et al. T cells in monoclonal gammopathies. *Scand J Haematol* 1982;29:57–64.
152. Mills KH, Cawley JC. Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. *Br J Haematol* 1983;53:271–275.
153. Osterborg A, Nilsson B, Bjorkholm M, et al. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. *Eur J Haematol* 1990;45:153–157.
154. Pilarski LM, Mant MJ, Ruether BA, et al. Abnormal clonogenic potential of T cells from multiple myeloma patients. *Blood* 1985;66:1266–1271.
155. Maecker B, Anderson KS, von Bergwelt-Baildon MS, et al. Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. *Br J Haematol* 2003;121:842–848.
156. Dhodapkar MV, Geller MD, Chang DH, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. *J Exp Med* 2003;197:1667–1676.
157. Song W, van der Vliet HJ, Tai YT, et al. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. *Clin Cancer Res* 2008;14:6955–6962.
158. Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. *Blood* 2006;107:301–304.
159. Gorgun GT, Whitehill G, Anderson JL, et al. Tumor-promoting immunosuppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. *Blood* 2013;121:2975–2987.
160. Yi Q, Osterborg A, Bergenbrant S, et al. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. *Blood* 1995;86:3043–3049.
161. Yi Q, Osterborg A. Idiotype-specific T cells in multiple myeloma: targets for an immunotherapeutic intervention? *Med Oncol* 1996;13:1–7.
162. Radl J, Croese JW, Zurcher C, et al. Animal model of human disease. Multiple myeloma. *Am J Pathol* 1988;132:593–597.
163. Feo-Zuppari FJ, Taylor CW, Iwato K, et al. Long-term engraftment of fresh human myeloma cells in SCID mice. *Blood* 1992;80:2843–2850.
164. Tassone P, Neri P, Carrasco DR, et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. *Blood* 2005;106:713–716.
165. Urashima M, Chen BP, Chen S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. *Blood* 1997;90:754–765.
166. Yacoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. *Blood* 1998;92:2908–2913.
167. Carrasco DR, Sukhdeo K, Protopopova M, et al. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. *Cancer Cell* 2007;11:349–360.
168. Iwakoshi NN, Lee AH, Vallabhajosyula P, et al. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. *Nat Immunol* 2003;4:321–329.
169. Chesi M, Robbiani DF, Sebag M, et al. AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. *Cancer Cell* 2008;13:167–180.
170. Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins [see comments]. *N Engl J Med* 1991;324:1845–1851.
171. Khamlichi AA, Rocca A, Touchard G, et al. Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model. *Blood* 1995;86:3655–3659.
172. Pozzi C, Fogazzi GB, Banfi G, et al. Renal disease and patient survival in light chain deposition disease. *Clin Nephrol* 1995;43:281–287.
173. Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. *Blood Rev* 1999;13:79–90.
174. Huang ZQ, Sanders PW. Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. *J Clin Invest* 1997;99:732–736.
175. Kyle RA, Greipp PR. Amyloidosis (AL): clinical and laboratory features in 229 cases. *Mayo Clin Proc* 1983;58:665–683.
176. Fattori E, Della Rocca C, Costa P, et al. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. *Blood* 1994;83:2570–2579.
177. Mundy GR, Raisz LC, Cooper RA, et al. Evidence for the secretion of an osteoclast stimulating factor in myeloma. *N Engl J Med* 1974;291:1041–1046.

178. Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphoma. *Cancer* 1997;80:1557–1563.
179. Bataille R, Manolagas SC, Berenson JR. Pathogenesis and management of bone lesions in multiple myeloma. *Hematol Oncol Clin North Am* 1997;11:349–361.
180. Cozzolino F, Torcia M, Aldinucci D, et al. Production of interleukin-1 by bone marrow myeloma cells. *Blood* 1989;74:380–387.
181. Garrett R, Durie B, Nedwin G, et al. Production of lymphotoxin, a bone resorbing cytokine, by cultured human myeloma cells. *N Engl J Med* 1987;317:526–532.
182. Oba Y, Lee JW, Ehrlich LA, et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. *Exp Hematol* 2005;33:272–278.
183. Tricot G. New Insights into role of microenvironment in multiple myeloma. *Lancet* 2000;355:248–250.
184. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* 1998;93:165–176.
185. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [see comments]. *Cell* 1997;89:309–319.
186. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. *N Engl J Med* 2003;349:2483–2494.
187. Fulcinitti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. *Blood* 2009;114:371–379.
188. Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. *Proc Natl Acad Sci U S A* 2010;107:5124–5129.
189. Broder S, Humphrey R, Durm M, et al. Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma. Role of suppressor cells. *N Engl J Med* 1975;293:887–892.
190. Jacobson DR, Zolla-Pazner S. Immunosuppression and infection in multiple myeloma. *Semin Oncol* 1986;13:282–290.
191. Cook G, Campbell JD, Carr CE, et al. Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. *J Leukoc Biol* 1999;66:981–988.
192. Wu KL, van Wieringen W, Vellenga E, et al. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. *Haematologica* 2005;90:996–997.
193. Paradisi F, Corti G, Cinielli R. Infections in multiple myeloma. *Infect Dis Clin North Am* 2001;15:373–384, vii–viii.
194. Soubrier MJ, Dubost JJ, Sauvezie BJM. Syndrome of FSGoP. POEMS syndrome: a study of 25 cases and a review of the literature. *Am J Med* 1994;97:543–553.
195. Lacy MQ, Certz MA, Hanson CA, et al. Multiple myeloma associated with diffuse osteosclerotic bone lesions: a clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). *Am J Hematol* 1997;56:288–293.
196. Miralles GD, O'Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. *N Engl J Med* 1992;327:1919–1923.
197. Waldenström JG, Adner A, Cydell K, et al. Osteosclerotic “plasmocytoma” with polyneuropathy, hypertrichosis and diabetes. *Acta Medica Scandinavica* 1978;203(4):297–303.
198. Leifer D, Grabowski T, Simonian N, et al. Leptomeningeal myelomatosis presenting with mental status changes and other neurologic findings. *Cancer* 1992;70:1899–1904.
199. Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. *Br J Haematol* 2002;117:103–108.
200. Dispenzieri A, Kyle RA. Neurological aspects of multiple myeloma and related disorders. *Best Pract Res Clin Haematol* 2005;18:673–688.
201. Pruzanski W, Watt JG. Serum viscosity and hyperviscosity syndrome in IgG multiple myeloma. Report on 10 patients and a review of the literature. *Ann Intern Med* 1972;77:853–860.
202. Preston FE, Cooke KB, Foster ME, et al. Myelomatosis and the hyperviscosity syndrome. *Br J Haematol* 1978;38:517–530.
203. Chandy KG, Stockley RA, Leonard RC, et al. Relationship between serum viscosity and intravascular IgA polymer concentration in IgA myeloma. *Clin Exp Immunol* 1981;46:653–661.
204. Capra JD, Kunkel HG. Aggregation of gamma-G3 proteins: relevance to the hyperviscosity syndrome. *J Clin Invest* 1970;49:610–621.
205. Perkins HA, MacKenzie MR, Fudenberg HH. Hemostatic defects in dysproteinemias. *Blood* 1970;35:695–707.
206. Lackner H. Hemostatic abnormalities associated with dysproteinemias. *Semin Hematol* 1973;10(2):125–133.
207. Elice F, Fink L, Tricot G, et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. *Br J Haematol* 2006;134:399–405.
208. Deitcher SR, Erban JK, Limentani SA. Acquired free protein S deficiency associated with multiple myeloma: a case report. *Am J Hematol* 1996;51:319–323.
209. Coleman M, Vigliano EM, Weksler ME, et al. Inhibition of fibrin monomer polymerization by lambda myeloma globulins. *Blood* 1972;39:210–223.
210. Furie B, Greene E, Furie BC. Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X. *N Engl J Med* 1977;297:81–85.
211. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. *Blood* 2001;98:1614–1615.
212. Zangari M, Saghaifir F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. *Blood Coagul Fibrinolysis* 2002;13:187–192.
213. Barlogie B, Smallwood L, Smith T, et al. High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma. *Ann Intern Med* 1989;110:521–525.
214. Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease in the era of novel agents. *Haematologica* 2012;97:1761–1767.
215. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. *Br J Haematol* 2003;121:749–757.
216. Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. *Blood* 2011;117:4701–4705.
217. Anderson K. Multiple myeloma: advances reported in 2013 are useful in the clinic. *J Natl Compr Canc Netw* 2014;12(5 Suppl):808–811.
218. Pizzolato M, Bragantini G, Bresciani P, et al. IgG1-kappa biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism. *Br J Haematol* 1998;102:503–508.
219. Zent CS, Wilson CS, Tricot G, et al. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. *Blood* 1998;91:3518–3523.
220. Kozuru M, Uike N, Takahira H, et al. Immunoglobulin class switch from IgA1 to IgG2 and simultaneous association with Bence Jones proteinuria in the escape phase in a myeloma patient treated with interferon alpha. *Br J Haematol* 1997;98:114–118.
221. Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. *Blood* 2014;123:3073–3079.
222. Rajkumar SV, Kyle RA, Thernau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. *Blood* 2005;106:812–817.
223. Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. *Blood* 2006;107:3378–3383.
224. Mead GP, Carr-Smith HD, Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. *Br J Haematol* 2004;126:348–354.
225. Shaw GR. Nonsecretory plasma cell myeloma—becoming even more rare with serum free light-chain assay: a brief review. *Arch Pathol Lab Med* 2006;130:1212–1215.
226. van Rhee F, Bolejack V, Hollmig K, et al. High serum free-light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. *Blood* 2007;110:827–832.
227. Ludwig H, Milosavljevic D, Zojer N, et al. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. *Leukemia* 2013;27:213–219.
228. Bradwell A, Harding S, Fourrier N, et al. Prognostic utility of intact immunoglobulin Ig kappa/lambda ratios in multiple myeloma patients. *Leukemia* 2013;27:202–207.
229. Barlogie B, Gale RP. Multiple myeloma and chronic lymphocytic leukemia: commonalities and differences in biology and therapy. *Leuk Lymph* 1991:27–32.
230. Bartl R, Frisch B. Clinical significance of bone marrow biopsy and plasma cell morphology in MM and MGUS. *Pathol Biol (Paris)* 1999;47:158–168.
231. Barlogie B, Alexanian R, Pershouse M, et al. Cytoplasmic immunoglobulin content in multiple myeloma. *J Clin Invest* 1985;76:765–769.
232. Mariette X, Khalifa P, Ravaud P, et al. Bone densitometry in patients with multiple myeloma [see comments]. *Am J Med* 1992;93:595–598.
233. Mariette X, Bergot C, Ravaud P, et al. Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy. *Cancer* 1995;76:1559–1563.
234. Chodimella U, Dhodapkar M, Weinstein R, et al. Differential effects of pamidronate (PAM) on cortical and cancellous bone in patients with myeloma (MM) undergoing autotransplants (AT). *Proc ASCO* 1998;10.
235. Moulouopoulos LA, Dimopoulos MA, Smith T, et al. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. *J Clin Oncol* 1995;13:251–256.
236. Vande Berg BC, Lecouvet FE, Michaux L, et al. Magnetic resonance imaging of the bone marrow in hematological malignancies. *Eur Radiol* 1998;8:1335–1344.
237. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. *J Clin Oncol* 2007;25:1121–1128.
238. Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. *Blood* 2009;114:2068–2076.

239. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. *Leukemia* 2009;23:1545–1556.
240. el-Shirbiny AM, Yeung H, Imbriaco M, et al. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. *J Nucl Med* 1997;38:1208–1210.
241. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. *Haematologica* 2007;92:50–55.
242. Durie B, Salmon S. Clinical staging system for myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. *Cancer* 1975;36:842–854.
243. Child JA, Norfolk DR, Cooper EH. Serum beta 2-microglobulin in myelomatosis [letter]. *Br J Haematol* 1986;63:406–407.
244. Garewal H, Durie BG, Kyle RA, et al. Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. *J Clin Oncol* 1984;2:51–57.
245. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. *N Engl J Med* 2003;349:2495–2502.
246. Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cyto-genetique Hematologique. *Blood* 2001;97:822–825.
247. Vesole DH, Tricot G, Jagannath S, et al. Autotransplants in multiple myeloma: what have we learned? *Blood* 1996;88:838–847.
248. Witzig TE, Gertz MA, Lust JA, et al. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma [see comments]. *Blood* 1996;88:1780–1787.
249. Witzig TE, Gonchoroff NJ, Katzmann JA, et al. Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. *J Clin Oncol* 1988;6:1041–1046.
250. Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]. *Blood* 1993;81:3382–3387.
251. Munshi N, Wilson C, Penn J, et al. Angiogenesis in newly diagnosed multiple myeloma (MM): poor prognosis with increased microvessel density (MVD) in bone marrow biopsies (BMBX). *Blood* 1998;92:98A.
252. Mathiot C, Galon J, Tartour E, et al. Soluble CD16 in plasma cell dyscrasias. *Leuk Lymph* 1999;32:467–474.
253. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. *Blood* 2011;117:4696–4700.
254. Dimopoulos MA, Mouloupos A, Delasalle K, et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. *Hematol Oncol Clin North Am* 1992;6:359–369.
255. Mill WB, Griffith R. The role of radiation therapy in the management of plasma cell tumors. *Cancer* 1980;45:647–652.
256. Liebross RH, Ha CS, Cox JD, et al. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. *Int J Radiat Oncol Biol Phys* 1998;41:1063–1067.
257. Corwin J, Lindberg RD. Solitary plasmacytoma of bone vs. extramedullary plasmacytoma. *Cancer* 1979;43:1007–1013.
258. Woodruff RK, Malpas JS, White FE. Solitary plasmacytoma. II: Solitary plasmacytoma of bone. *Cancer* 1979;43:2344–2347.
259. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. *N Engl J Med* 2007;356:2582–2590.
260. Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. *Blood* 2008;111:785–789.
261. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. *Leukemia* 2003;17:775–779.
262. Mateos MV, San Miguel JF. Treatment for high-risk smoldering myeloma. *N Engl J Med* 2013;369:1764–1765.
263. Bergsagel DE, Sprague CC, Austin C, et al. Evaluation of new chemotherapeutic agents in the treatment of myeloma IV: phenylalanine mustard. *Cancer Chemother Rep*. 1962;21:87.
264. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. *JAMA* 1969;208:1680–1685.
265. Boccadoro M, Marmont F, Tribalto M, et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. *J Clin Oncol* 1991;9:444–448.
266. Palva IP, Ahrenberg P, Ala Harja K, et al. Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group. *Eur J Haematol* 1990;44:121–124.
267. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. *N Engl J Med* 1984;310:1353–1356.
268. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. *Blood* 2005;106:35–39.
269. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. *Lancet Oncol* 2010;11:29–37.
270. Mandelli F, Avisati F, Amadori S, et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. *N Engl J Med* 1990;322:1430–1434.
271. Gisslinger H. Interferon alpha in the therapy of multiple myeloma. *Leukemia* 1997;11:S52–S56.
272. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. *J Clin Oncol* 2006;24:929–936.
273. Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. *Oncology* 2000;14:101–111.
274. Woodruff RK, Whittle JM, Malpas JS. Solitary plasmacytoma. I: Extramedullary soft tissue plasmacytoma. *Cancer* 1979;43:2340–2343.
275. Wallington M, Mendis S, Premawardhana U, et al. Local control and survival in spinal cord compression from lymphoma and myeloma. *Radiother Oncol* 1997;42:43–47.
276. Rowell NP, Tobias JS. The role of radiotherapy in the management of multiple myeloma. *Blood Rev* 1991;5:84–89.
277. Raju N, Anderson K. Thalidomide—a revival story [editorial; comment]. *New Engl J Med* 1999;341:1606–1609.
278. Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. *Science* 2014;343:301–305.
279. Lu C, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblin-dependent destruction of Ikaros proteins. *Science* 2014;343:305–309.
280. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. *Blood* 2001;98:492–494.
281. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [see comments]. *N Engl J Med* 1999;341:1565–1571.
282. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. *Leukemia* 2008;22:414–423.
283. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. *Blood* 2002;100:3063–3067.
284. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. *N Engl J Med* 2007;357:2133–2142.
285. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med* 2014;371:906–917.
286. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. *Nat Rev Cancer* 2002;2:927–937.
287. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor- $\kappa$ B blockade in multiple myeloma: therapeutic applications. *Blood* 2002;99:4079–4086.
288. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. *Cancer Res* 2001;61:3071–3076.
289. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. *Proc Natl Acad Sci U S A* 2002;99:14374–14379.
290. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. *N Engl J Med* 2003;348:2609–2617.
291. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *N Engl J Med* 2005;352:2487–2498.
292. Orlowski RZ, Zhuang SH, Parekh T, et al. The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: results from a planned interim analysis of a randomized phase III study. *Blood* 2006;108:404.
293. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. *Leukemia* 2007;21:151–157.
294. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. *Blood* 2007;109:2604–2606.
295. Zangari M, Esseltine D, Lee CK, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. *Br J Haematol* 2005;131:71–73.
296. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. *Lancet Oncol* 2011;12:431–440.
297. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. *J Clin Oncol* 2006;24:431–436.

298. Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). *Blood* 2010;116:5838–5841.
299. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. *Br J Haematol* 2004;127:165–172.
300. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. *J Clin Oncol* 2010;28:4621–4629.
301. Avet-Loiseau H, Lelou X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). *J Clin Oncol* 2010;28:4630–4634.
302. Jakubowiak AJ, Dytfield D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a front-line treatment for multiple myeloma. *Blood* 2012;120:1801–1809.
303. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. *Leukemia* 2009;23:1337–1341.
304. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. *Blood* 2010;116:679–686.
305. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N Engl J Med* 2008;359:906–917.
306. Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. *J Clin Oncol* 1994;12:759–763.
307. Bensinger WI, Rowley SD, Demirew T, et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. *J Clin Oncol* 1996;14:1447–1456.
308. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous blood stem cell transplantation in multiple myeloma: preliminary results of a randomized trial involving 167 patients. *Stem Cells* 1995;13:156–159.
309. Anderson KC, Andersen J, Soiffer R, et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. *Blood* 1993;82:2568–2576.
310. Harousseau JL, Attal M, Divine M, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma. *Stem Cells* 1995;13:132–139.
311. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome. *N Engl J Med* 1996;335:91–97.
312. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. *N Engl J Med* 2003;348:1875–1883.
313. Blade J, Surenda A, Diaz-Mediavilla J, et al. High-dose therapy autotransplantation/intensification vs continued conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy. Results of a prospective randomized trial from the Spanish Cooperative group PETHEMA. *Blood* 2001;98:815a.
314. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. *Blood* 1998;92:3131–3136.
315. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. *Biol Blood Marrow Transplant* 2007;13:183–196.
316. Harousseau JL, Milpied N, Laporte JP, et al. Double-intensive therapy in high-risk multiple myeloma. *Blood* 1992;79:2827–2833.
317. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. *Blood* 1999;93:55–65.
318. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplant for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. *Blood* 1995;85:588.
319. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. *Leukemia* 2007;21:2035–2042.
320. Mark T, Stern J, Furst JR, et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. *Biol Blood Marrow Transplant* 2008;14:795–798.
321. Kumar S, Giralt S, Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. *Blood* 2009;114:1729–1735.
322. Vesole DH, Barlogie B, Jagannath S, et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. *Blood* 1994;84:950–956.
323. Certz MA, Lacy MQ, Inwards DJ, et al. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. *Bone Marrow Transplant* 1999;23:221–226.
324. Barlogie B, Dicke KA, Alexanian R. High dose melphalan for refractory myeloma—the M.D. Anderson experience. *Hematol Oncol* 1988;6:167–172.
325. Desikan KR, Ffass A, Siegel D, et al. Superior outcome with melphalan 200 mg/m<sup>2</sup> (MEL 200) for scheduled second autotransplant compared to MEL+TBI or CTX for myeloma (MM) in pre-tx-2 PR. *Blood* 1997;90:231a.
326. Jagannath S, Barlogie B. Autologous bone marrow transplantation for multiple myeloma. *Hematol Oncol Clin North Am* 1992;6:437–449.
327. Fermand JP, Levy Y, Gerota J, et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. *Blood* 1989;73:20–23.
328. Ventura GJ, Barlogie B, Hester JP, et al. High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma. *Bone Marrow Transplant* 1990;5:265–268.
329. Vescio RA, Hong CH, Cao J, et al. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. *Blood* 1994;84:3283–3290.
330. Schiller G, Vescio R, Freytes C, et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. *Blood* 1995;86:390–397.
331. Stewart AK, Vescio R, Schiller G, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. *J Clin Oncol* 2001;19:3771–3779.
332. Gazitt Y, Reading CC, Hoffman R, et al. Purified CD34+Lin-Thy+ stem cells do not contain clonal myeloma cells. *Blood* 1995;86:381–389.
333. Tricot G, Gazitt Y, Leemhuis T, et al. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. *Blood* 1998;91:4489–4495.
334. Harousseau JL, Attal M, Divine M, et al. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. *Bone Marrow Transplant* 1995;15:963–969.
335. Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. *Blood* 1995;85:588–596.
336. Gazitt Y, Tian E, Barlogie B, et al. Differential mobilization of myeloma cells and normal hematopoietic stem cells in multiple myeloma after treatment with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. *Blood* 1996;87:805–811.
337. Palumbo A, Anderson K. Multiple myeloma. *N Engl J Med* 2011;364:1046–1060.
338. Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. *J Clin Oncol* 2014;32:587–600.
339. Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. *Blood* 1999;93:51–54.
340. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. *Br J Haematol* 2001;114:600–607.
341. Tricot G, Alberts DS, Johnson C, et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. *Clin Cancer Res* 1996;2:947–952.
342. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. *J Clin Oncol* 2010;30:4976–4984.
343. Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. *Br J Haematol* 2001;114:822–829.
344. Browman G, Bergsagel D, Sicheri D, et al. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 1995;13:2354–2360.
345. Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. *Blood* 2002;99:3163–3168.
346. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. *Blood* 2006;108:3289–3294.
347. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. *N Engl J Med* 2012;366:1782–1791.
348. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. *N Engl J Med* 2012;366:1770–1781.
349. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med* 2012;366:1759–1769.
350. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. *J Clin Oncol* 2012;30:2946–2955.
351. Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with

- untreated multiple myeloma: a randomised trial. *Lancet Oncol* 2010;11:934–941.
352. Rosenblatt J, Vasir B, Uhl L, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. *Blood* 2011;117:393–402.
  353. Rosenblatt J, Avivi I, Vasir B, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. *Clin Cancer Res* 2013;19:3640–3648.
  354. Munshi NC, Anderson KC. Minimal residual disease in multiple myeloma. *J Clin Oncol* 2013;31:2523–2526.
  355. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. *J Clin Oncol* 2013;31:2540–2547.
  356. Paiva B, Gutierrez NC, Rosinol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. *Blood* 2012;119:687–691.
  357. Bensinger WI, Demirer T, Buckner CD, et al. Syngeneic marrow transplantation in patients with multiple myeloma. *Bone Marrow Transplant* 1996;18:527–531.
  358. Gahrton G, Svensson H, Björkstrand B, et al. Syngeneic transplantation in multiple myeloma—a case matched comparison with autologous and allogeneic transplantation. *Bone Marrow Transpl* 1999;24:741–745.
  359. Björkstrand B, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. *Blood* 1996;88:4711–4718.
  360. Aleya EP, Anderson KC. Allogeneic transplantation for multiple myeloma. *Cancer J* 2001;7:166–174.
  361. Mehta J, Tricot G, Jagannath S, et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? *Bone Marrow Transplant* 1998;21:887–892.
  362. Tricot G, Vesole DH, Jagannath S, et al. Graft-versus-myeloma effect: proof of principle. *Blood* 1996;87:1196–1198.
  363. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. *Blood* 2000;18:3031–3037.
  364. Salama M, Nevill T, Marcellus D, et al. Donor leukocyte infusions for multiple myeloma. *Bone Marrow Transplant* 2000;26:1179–1184.
  365. Munshi NC, Govindarajan R, Drake R, et al. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional and are killed efficiently with ganciclovir. *Blood* 1997;89:1334–1340.
  366. Soiffer RJ, Aleya EP, Hochberg E, et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. *Biol Blood Marrow Transplant* 2002;8:625–632.
  367. Storb R, Yu C, Zauha JM, et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4g, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. *Blood* 1999;94:2523–2529.
  368. Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. *J Clin Oncol* 2002;20:1295–1303.
  369. Giralt S, Aleman A, Anagnostopoulos A, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. *Bone Marrow Transplant* 2002;30:367–373.
  370. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. *Blood* 2003;102:3447–3454.
  371. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. *N Engl J Med* 2007;356:1110–1120.
  372. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. *Blood* 2008;112:3591–3593.
  373. Lokhorst H, Einsele H, Vesole D, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. *J Clin Oncol* 2010;28:4521–4530.
  374. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. *Lancet Oncol* 2011;12:1195–1203.
  375. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. *N Engl J Med* 1996;334:488–493.
  376. Apperley JF, Croucher PJ. Bisphosphonates in multiple myeloma. *Pathol Biol (Paris)* 1999;47:178–181.
  377. Berenson JR, Lipton A. Bisphosphonates in the treatment of malignant bone disease. *Ann Rev Med* 1999;50:237–248.
  378. Shipman CM, Croucher PJ, Russell RG, et al. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. *Cancer Res* 1998;58:5294–5297.
  379. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. *J Clin Oncol* 1998;16:593–602.
  380. Aparicio A, Gardner A, Tu Y, et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. *Leukemia* 1998;12:220–229.
  381. Shipman CM, Rogers MJ, Apperley JF, et al. Anti-tumour activity of bisphosphonates in human myeloma cells. *Leuk Lymph* 1998;32:129–138.
  382. Dhodapkar MV, Singh J, Mehta J, et al. Anti-myeloma activity of pamidronate in vivo. *Br J Haematol* 1998;103:530–532.
  383. Morgan GJ, Child JA, Gregory WM, et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. *Lancet Oncol* 2011;12:743–752.
  384. Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. *Lancet* 2010;376:1989–1999.
  385. Wang EP, Kaban LB, Strewler GJ, et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. *J Oral Maxillofac Surg* 2007;65:1328–1331.
  386. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. *J Clin Oncol* 2007;25:2464–2472.
  387. Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. *J Clin Oncol* 2003;21:2732–2739.
  388. Jagannath S, Vij R, Stewart AK, et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. *Clin Lymphoma Myeloma Leuk* 2012;12:310–318.
  389. Vij R, Siegel DS, Jagannath S, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. *Br J Haematol* 2012;158:739–748.
  390. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. *Blood* 2012;120:2817–2825.
  391. Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma. *Blood* 2012;119:5661–5670.
  392. Jakubowiak AJ, Siegel DS, Martin T, et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. *Leukemia* 2013;27:2351–2356.
  393. Lacy MQ, Allred JB, Gertz MA, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. *Blood* 2011;118:2970–2975.
  394. Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC-4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. *J Clin Oncol* 2009;27:5008–5014.
  395. Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. *Blood* 2013;121:1961–1967.
  396. Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. *Blood* 2013;121:1968–1975.
  397. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2013;14:1055–1066.
  398. Richardson PG, Hofmeister CG, Siegel D, et al. MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). *Blood* 2013;122:1969. [ePub ahead of Print].
  399. Dimopoulos M, Siegel DS, Lonial S, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. *Lancet Oncol* 2013;14:1129–1140.
  400. Santo L, Hideshima T, Kung AL, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. *Blood* 2012;119:2579–2589.
  401. Richardson PG, Eng C, Kolesar J, et al. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. *Expert Opin Drug Metab Toxicol* 2012;8:623–633.
  402. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. *Lancet* 2006;367:825–831.
  403. Facon T, Mary JY, Hulín C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. *Lancet* 2007;370:1209–1218.

404. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. *J Clin Oncol* 2009;27:3664–3670.
405. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study. *J Clin Oncol* 2010;28:3160–3166.
406. Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. *Blood* 2010;116:1405–1412.
407. Sonneveld P, van der Holt B, Segeren CM, et al. Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. *Haematologica* 2007;92:928–935.
408. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. *J Clin Oncol* 2007;25:2434–2441.
409. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. *J Clin Oncol* 2009;27:1788–1793.
410. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. *N Engl J Med* 2006;354:1021–1030.
411. Lee CK, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. *Exp Hematol* 2003;31:73–80.
412. Lee CK, Badros A, Barlogie B, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. *Exp Hematol* 2003;31:73–80.
413. Belch AR, Bergsagel DE, Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. *J Clin Oncol* 1991;9:1397–1402.
414. Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. *Lancet* 1992;340:1049–1052.